NCT03787927 (R-DAPT) is a Phase 1, PHASE2 clinical trial of Autologous Platelet Transfusion (room-temperature-stored) in Bleeding, sponsored by Bloodworks.

Who is sponsoring NCT03787927?

NCT03787927 is sponsored by Bloodworks.

What drugs are being tested in NCT03787927?

Interventions in NCT03787927: Autologous Platelet Transfusion (room-temperature-stored), Autologous Platelet Transfusion (cold-stored 5 days), Autologous Platelet Transfusion (cold-stored 10 days), Autologous Platelet Transfusion (cold-stored 15 days), Aspirin, Clopidogrel.

What condition does NCT03787927 study?

NCT03787927 studies Bleeding, Platelet Dysfunction Due to Drugs, Platelet Dysfunction.

Is NCT03787927 still recruiting?

NCT03787927 is currently status unknown. Last updated 14 July 2020.

Last reviewed 2020-07-14 · How we verify

NCT03787927: R-DAPT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reversal of Dual Antiplatelet Therapy With Cold Stored Platelets

Status unknown Phase 1, PHASE2 Last updated 14 July 2020

What this trial tests

Phase 1, PHASE2 trial testing Autologous Platelet Transfusion (room-temperature-stored) in Bleeding in 60 participants. Status unknown.

Timeline

3 December 2018

Primary endpoint
3 December 2021

3 December 2021

Quick facts

Lead sponsor	Bloodworks
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	3 December 2018
Primary completion	3 December 2021
Estimated completion	3 December 2021
Sites	1 location across United States

Drugs / interventions tested

Autologous Platelet Transfusion (room-temperature-stored) — full drug profile →
Autologous Platelet Transfusion (cold-stored 5 days) — full drug profile →
Autologous Platelet Transfusion (cold-stored 10 days) — full drug profile →
Autologous Platelet Transfusion (cold-stored 15 days) — full drug profile →
Aspirin
Clopidogrel (clopidogrel) — full drug profile →

Conditions studied

Bleeding — all drugs for Bleeding →
Platelet Dysfunction Due to Drugs — all drugs for Platelet Dysfunction Due to Drugs →
Platelet Dysfunction — all drugs for Platelet Dysfunction →

Sponsor

Bloodworks — full company profile →

Who can join

Adults 18 to 59, any sex, with Bleeding or Platelet Dysfunction Due to Drugs. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to determine whether cold-stored platelets (CSP) are equally, more effective, or uniquely effective at reversing the effect of dual antiplatelet therapy in healthy human subjects compared to room-temperature-stored platelets (RTP). The investigators plan to enroll healthy human subjects without risk factors for bleeding to achieve 60 complete data sets. Each subject will donate two apheresis platelet units. One platelet unit will be stored in the cold (CSP) and one platelet unit will be stored at room temperature (RTP). Subjects will be given dual anti-platelet therapy (aspirin and clopidogrel) prior to autologous transfusion of each unit. Platelet function testing will be performed before and after transfusion to measure reversal of the antiplatelet drugs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Bleeding

Currently open trials in the same condition.

NCT07401394 — BAR-TAX - Tranexamic Acid in Bariatric Surgery. · NA · active not recruiting
NCT07309848 — Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs · recruiting
NCT07083583 — Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders · recruiting
NCT07019077 — Incidence of Late Haemorrhage After Invasive Gastroenterological Endoscopic Manoeuvre in Patients Treated With Anticoagu · recruiting
NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery. · active not recruiting

Other Bloodworks trials

Trials by the same sponsor.

NCT07513532 — The Primary Purpose of This Study is to Determine if Biotin, Vitamin B7 is an Effective Way to Label Platelets in Surviv · Phase 1 · not yet recruiting
NCT03358836 — Joint Health Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03787927 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bloodworks
Last refreshed: 14 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03787927.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing